Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?-Reference-Cited by-同舟云学术

Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?

Published:2020-10 Issue:11 Volume:26 Page:2199-2202
ISSN:1075-122X
Container-title:The Breast Journal
language:en
Short-container-title:Breast J

Author:

Kapadia Sonam¹^ORCID,Gudiwada Sai Priyanka²,Kaji Amy H.³,Chlebowski Rowan T.⁴,Venegas Rose²,Ozao‐Choy Junko¹,Dauphine Christine¹^ORCID

Affiliation:

1. Department of Surgery Harbor‐UCLA Medical Center Torrance CA USA

2. Department of Pathology Harbor‐UCLA Medical Center Torrance CA USA

3. Department of Emergency Medicine Harbor‐UCLA Medical Center Torrance CA USA

4. Department of Medicine, Division of Medical Oncology Harbor‐UCLA Medical Center Torrance CA USA

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tbj.14068

Reference13 articles.

1. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

2. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

3. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

4. TAILORx: Trial Assigning Individualized Options for Treatment (Rx)

5. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer;Cancers;2024-08-23

2. A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX ® testing to guide adjuvant chemotherapy decisions;Cancer Treatment and Research Communications;2023

3. Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use;Breast Cancer Research;2021-07-17

4. Clinical Impact of a Novel Model Predictive of Oncotype DX Recurrence Score in Breast Cancer;In Vivo;2021